Price Action Don’t Lie: Genocea Biosciences Inc Can’t Burn Your Short Portfolio. Has Another Weak Session

Price Action Don't Lie: Genocea Biosciences Inc Can't Burn Your Short Portfolio. Has Another Weak Session

The stock of Genocea Biosciences Inc (NASDAQ:GNCA) is a huge mover today! The stock decreased 4.10% or $0.21 during the last trading session, hitting $4.91. About 735,826 shares traded hands or 80.94% up from the average. Genocea Biosciences Inc (NASDAQ:GNCA) has risen 21.53% since March 1, 2016 and is uptrending. It has outperformed by 9.32% the S&P500.
The move comes after 6 months negative chart setup for the $140.97 million company. It was reported on Oct, 4 by We have $4.32 PT which if reached, will make NASDAQ:GNCA worth $16.92 million less.

Analysts await Genocea Biosciences Inc (NASDAQ:GNCA) to report earnings on November, 3. They expect $-0.42 earnings per share, down 13.51% or $0.05 from last year’s $-0.37 per share. After $-0.39 actual earnings per share reported by Genocea Biosciences Inc for the previous quarter, Wall Street now forecasts 7.69% negative EPS growth.

Genocea Biosciences Inc (NASDAQ:GNCA) Ratings Coverage

Out of 4 analysts covering Genocea Biosciences (NASDAQ:GNCA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Genocea Biosciences has been the topic of 7 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Needham on Thursday, September 29. The firm has “Overweight” rating given on Thursday, August 6 by Piper Jaffray. UBS initiated the shares of GNCA in a report on Thursday, December 17 with “Buy” rating. As per Monday, October 19, the company rating was maintained by FBR Capital. The firm has “Buy” rating given on Tuesday, August 11 by Needham. On Thursday, September 29 the stock rating was maintained by PiperJaffray with “Overweight”. The firm earned “Buy” rating on Tuesday, October 20 by Needham.

According to Zacks Investment Research, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts.”

More notable recent Genocea Biosciences Inc (NASDAQ:GNCA) news were published by: which released: “Genocea Biosciences Posts Positive Herpes Trial Results” on September 29, 2016, also with their article: “Why It’s Been a Wild Few Days for Genocea Biosciences Inc.” published on April 01, 2016, published: “/quotes/zigman/3870025/realtime” on February 05, 2014. More interesting news about Genocea Biosciences Inc (NASDAQ:GNCA) were released by: and their article: “Why Genocea Biosciences Inc Stock Dropped Today” published on July 30, 2015 as well as‘s news article titled: “Genocea Biosciences Shares Dive as Vaccine Candidate Misses Goals” with publication date: October 19, 2015.

GNCA Company Profile

Genocea Biosciences, Inc., incorporated on August 16, 2006, is a biopharmaceutical company. The Firm discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses, in contrast to approved vaccines and immunotherapies, which are designed to act primarily through B cell (or antibody) immune responses. The Company’s ATLAS discovery platform is designed to overcome the challenges associated with developing vaccines that stimulate T cell immunity. The Company’s ATLAS is a throughput system for T cell vaccine and immunotherapy discovery. The Firm operates through business of developing and commercializing vaccines segment. The Firm has one product candidate in Phase II clinical development: GEN-003.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment